AFFILIATIONS
1 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
3 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
4 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
5 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
6 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
7 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
8 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
9 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Introduction: Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML). The intensity and antileukemic activity of conditioning regimens are important determinants of post-transplant disease control. Modified busulfan/cyclophosphamide (mBuCy) conditioning is widely used in AML; however, relapse remains a major concern in high-risk populations, underscoring the need for more effective conditioning strategies. Thiotepa is a tissue-penetrating alkylating agent with potent antileukemic and immunosuppressive activity, providing a strong rationale for its incorporation into busulfan-based conditioning. Thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has shown promise in other hematologic malignancies, but its comparative efficacy and safety versus mBuCy in high-risk AML have not been systematically evaluated.
Methods: We conducted a single-center retrospective cohort study of consecutive adults aged 18–65 years with high-risk AML, including those with European LeukemiaNet (ELN) 2022 adverse-risk disease, relapsed/refractory (R/R) disease, and/or extramedullary involvement, who underwent allo-HSCT between May 2022 and October 2025. Patients received TBC or mBuCy-based conditioning. Propensity scores included age at transplantation, ELN 2022 adverse-risk status, R/R disease, extramedullary involvement, remission status, pretransplant measurable residual disease (MRD), donor type, and antithymocyte globulin use. Patients were matched in a 1:2 ratio using nearest-neighbor matching without replacement and a caliper width of 0.20 standard deviations of the logit of the propensity score. The primary endpoint was leukemia-free survival (LFS). Secondary endpoints included overall survival (OS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), engraftment, graft-versus-host disease (GVHD), and transplant-related complications. LFS and OS were evaluated using the Kaplan-Meier method and weighted Cox models; competing-risk methods were used for CIR and NRM.
Results: Among 246 eligible patients, 42 received TBC conditioning and 204 received mBuCy-based conditioning. After 1:2 propensity score matching, all 42 TBC recipients were matched to 84 mBuCy recipients. All covariates included in the propensity score model achieved absolute standardized mean differences below 0.10. The median age was 39.2 years in the TBC group and 39.5 years in the mBuCy group; 57.1% and 61.9% had ELN 2022 adverse-risk disease, 38.1% and 36.9% had R/R disease, 21.4% and 17.9% had extramedullary involvement, and 61.9% and 58.3% were MRD-positive before transplantation, respectively.
At a median follow-up of 22.6 months, the 1-year LFS rate was significantly higher in the TBC group than in the mBuCy group (73.8% vs 53.2%; HR, 0.52; 95% CI, 0.29–0.94; P = 0.029). No statistically significant between-group differences were observed in 1-year OS (87.6% vs 70.1%; HR, 0.57; 95% CI, 0.28–1.15; P = 0.116), CIR (21.4% vs 36.1%; P = 0.176), or NRM (4.8% vs 10.7%; P = 0.208).
No primary graft failure occurred. Median times to neutrophil engraftment (11 vs 12 days; P = 0.074) and platelet engraftment (14 vs 13 days; P = 0.070) were similar between groups. The incidences of key transplant-related complications—including cytomegalovirus (CMV) DNAemia, Epstein-Barr virus (EBV) DNAemia, severe infection, grade 3–4 gastrointestinal mucositis, and sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)—did not differ significantly between groups (all P > 0.05). No transplant-associated thrombotic microangiopathy (TA-TMA) occurred. The incidences of grade II–IV acute GVHD (23.1% vs 16.2%; P = 0.603) and moderate-to-severe chronic GVHD (23.1% vs 16.4%; P = 0.615) were also comparable.
Conclusions: In this propensity score-matched analysis, TBC conditioning was associated with significantly better LFS than mBuCy conditioning in patients with high-risk AML. No statistically significant between-group differences were observed in OS, CIR, NRM, hematopoietic recovery, or major transplant-related complications. These findings suggest that TBC may be an effective conditioning option for selected patients with high-risk AML and warrant validation in larger prospective multicenter studies with longer follow-up.
DISCLOSURES
Xiaowen Tang, MD: No relevant conflicts of interest to declare.